Combined Detection of Urinary Micro Albumin, Î±1â€‘microglobulinand N-acetyl-Î²-D-glucosaminidase in the Early Diagnosis of Diabetic Nephropathy
Objective: To analyze the values of combined detection of urinary micro albumin (mAlb), Î±1â€‘microglobulin (Î±1-MG) and N-acetyl-Î²-D-glucosaminidase (NAG) in the early diagnosis of diabetic nephropathy (DN).
Methods: Ninety-four patients with early DN who were admitted to the hospital between April 2015 and April 2016 were selected and set as a DN group. Moreover, seventy-six patients with diabetes who were admitted to the hospital in the same period were selected and set as a diabetes group, and sixty-four healthy people were selected as set as a control group. The urinary mAlb, Î±1-MG and NAG of the three groups were detected. Moreover, the patients were divided into a favorable blood glucose control group and a poor blood glucose control group according to the blood glucose control condition of the patients. The detection results of the three groups were compared and statistically analyzed.
Results: The urinary mAlb, Î±1-MG and NAG levels of the DN group were significantly higher than those of the diabetes group and control group, and the differences had statistical significance (P<0.05). The detection indicator values of the favorable blood glucose control group were much lower than those of the poor blood glucose control group, and the difference was statistically significant (P<0.05). The positive rate of the combined detection of mAlb, Î±1-MG and NAG levels was 90.2%, which was much higher than that of single indicator (P<0.05).
Conclusion: Combined detection of urinary mAlb, Î±1-MG and NAG is sensitive in diagnosing early renal damages in DN patients.
How to cite this:Zhang X, Zhou H, Li Y. Combined Detection of Urinary Micro Albumin, Î±1â€‘microglobulin and N-acetyl-Î²-D-glucosaminidase in the Early Diagnosis of Diabetic Nephropathy. Pak J Med Sci. 2017;33(6):1324-1327.Â Â doi: https://doi.org/10.12669/pjms.336.13168
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- There are currently no refbacks.